The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Oppenheimer: Maintaining Protara Therapeutics ( Protara Therapeutics, Inc.(TARA.US) ) rating at "Outperform Market", while raising the price target from $25 to $28.

Piper Sandler: Maintain Bright Minds Biosciences' rating ( Bright Minds Biosciences(DRUG.US) ) at "Overweight", while raising the target price from $190 to $220.

Wells Fargo: Maintaining an "overweight" rating on WAVE Life Sciences ( Wave Life Sciences Ltd.(WVE.US) ), while raising the price target from $13 to $14.

Jefferies: Initial rating for SAB Biotherapeutics ( SAB Biotherapeutics Inc Ordinary Shares(SABS.US) ) at "Buy", with a target price of $11.

Rosenblatt: Maintaining a "buy" rating on Canaan Inc. ( Canaan Inc.(CAN.US) ), while lowering the price target from $2.25 to $1.3.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
Protara Therapeutics, Inc.(TARA.US)	to lift	$28.0	$4.76	488.24%	Oppenheimer
Bright Minds Biosciences(DRUG.US)	to lift	$220.0	$82.78	165.76%	Piper Sandler
Wave Life Sciences Ltd.(WVE.US)	to lift	$14.0	$6.19	126.17%	Wells Fargo
Relay Therapeutics, Inc.(RLAY.US)	to lift	$27.0	$13.02	107.37%	Barclays
Amer Sports, Inc.(AS.US)	to lift	$62.0	$34.84	77.96%	UBS
SAB Biotherapeutics Inc Ordinary Shares(SABS.US)	Initial classification	$11.0	$3.68	198.91%	Jefferies
Canaan Inc.(CAN.US)	cut	$1.3	$0.436	198.17%	Rosenblatt
SkinHealth Systems Inc. Class A(SKIN.US)	cut	$2.0	$0.6775	195.2%	Roth Capital
BETA Technologies, Inc. Class A(BETA.US)	cut	$33.0	$14.95	120.74%	BTIG
Karman Holdings Inc.(KRMN.US)	cut	$100.0	$65.76	52.07%	Keybanc

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

UBS: Maintaining a "buy" rating on Costco Costco Wholesale(COST.US) ) stock, while raising the price target from $1205 to $1275.

Wells Fargo: Maintaining Alphabet's ( Alphabet Inc. Class A(GOOGL.US) ) rating at "overweight", while raising the price target from $427 to $435.

Oppenheimer: Maintaining Marvell Technology's ( Marvell Technology, Inc.(MRVL.US) ) rating at "Outperform Market", while raising the price target from $170 to $200.

Wells Fargo: Maintaining Marvell Technology's ( Marvell Technology, Inc.(MRVL.US) ) rating at "overweight," while raising the target price from $135 to $195.

Morgan Stanley: Maintaining an "overweight" rating on Palo Alto Networks Palo Alto Networks, Inc.(PANW.US) ) stock, while raising the price target from $223 to $253.

Mizuho: Maintaining United Health's ( UnitedHealth Group Incorporated(UNH.US) ) rating at "Outperform Market," while raising the price target from $410 to $440.

TD Cowen: Maintaining a "buy" rating on Vertiv Holdings VERTIV HOLDINGS LLC(VRT.US) ), raising its price target from $347 to $387.

First Coverage

Needham: Preliminary rating for QuickLogic Corporation(QUIK.US) stock at "Buy", with a target price of $22.

Jefferies: Initial rating for SAB Biotherapeutics ( SAB Biotherapeutics Inc Ordinary Shares(SABS.US) ) at "Buy", with a target price of $11.

Cantor Fitzgerald: Initial rating for X-Energy ( X-Energy, Inc. Class A(XE.US) ) at "overweight", with a target price of $38.

reduction

Wells Fargo: Maintaining Amazon's ( Amazon.com, Inc.(AMZN.US) ) rating at "overweight," while lowering the target price from $313 to $312.

Wells Fargo: Maintaining an "overweight" rating on Meta Platforms Meta Platforms(META.US) ) stock, while lowering its price target from $770 to $765.

Freedom Broker: Downgraded TGT ( Target Corporation(TGT.US) ) stock rating to "Hold", with a price target cut from $145 to $130.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.